about
Current Chemotherapy and Potential New Targets in Uterine LeiomyosarcomaCDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsNovel interaction of ornithine decarboxylase with sepiapterin reductase regulates neuroblastoma cell proliferation.The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplificationCidofovir selectivity is based on the different response of normal and cancer cells to DNA damage.Differential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells.A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastomac-Myc as a therapeutic target in cancer.Mouse models of childhood cancer of the nervous systemCell survival signaling in neuroblastoma.A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.Development of anticancer drugs based on the hallmarks of tumor cells.AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression.Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.Functional prediction of miR-3144-5p in human cardiac myocytes based on transcriptome sequencing and bioinformatics.Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells.The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.Heterogeneity in retinoblastoma: a tale of molecules and models.
P2860
Q26767435-9461DE68-D102-454D-9517-90C09832DC98Q27670943-9578FB95-1056-4935-8848-B995ECE042DFQ33578405-5459C986-9640-42AF-8E3D-F9BC785B6D51Q33761692-14341DFE-5A0D-4659-92C1-A2E7B1ED48F3Q34736407-86D3C0A2-DD8C-4BFC-886D-C332B33182A5Q35248327-D4035618-31DA-4E7C-A9D9-02F7CA9A13AFQ35644191-5E46C10E-1A47-47AF-9374-BDF1F25D56D9Q35728765-F4FCE2CF-8F56-4821-8F6D-4122B2A2C020Q35786003-132A63AC-16B1-4AD3-ACDC-95257E72C763Q37010166-5FD498AA-7C5C-44FE-9047-8F3AF0DE32ECQ38083828-0FBE6871-82C7-490D-9E2A-690F2567A619Q38182491-63576F41-BB6C-44FB-9B25-C60F82A0BD77Q39185908-991939ED-7722-455B-A589-448CFE2159E7Q39188198-C01FD1E0-28CF-4387-B69F-9B584D8EC8D6Q39705986-A1FC9455-703E-4A4E-A4A3-3DB5AD3D8F8AQ40041609-C555B194-D742-4F53-A558-EE283EDD3D2EQ40088003-1BA18F68-C6D8-4B1F-88DF-B0352DF2EA2EQ40399480-E215250D-DDC4-406E-B08F-7ED405BA7A13Q42089520-98B30547-DDF2-4B45-8A22-DB48EEA379D6Q45895694-A7632DF6-33BF-470C-A3E6-6DCC3F530DBD
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The MYCN oncoprotein as a drug development target.
@ast
The MYCN oncoprotein as a drug development target.
@en
type
label
The MYCN oncoprotein as a drug development target.
@ast
The MYCN oncoprotein as a drug development target.
@en
prefLabel
The MYCN oncoprotein as a drug development target.
@ast
The MYCN oncoprotein as a drug development target.
@en
P2093
P1433
P1476
The MYCN oncoprotein as a drug development target.
@en
P2093
Andrew Pearson
John Lunec
Xiaohong Lu
P304
P356
10.1016/S0304-3835(03)00096-X
P407
P577
2003-07-01T00:00:00Z